Do cholinesterase inhibitors reduce Alzheimer pathology?
This project is examining the relatioship between choliesterase administration and amyloid and tau pathology in Alzheimer’s disease and dementia with Lewy bodies, focusing upon people treated with cholinesterase inhibitors in placebo controlled clinical trials and matched controls. The data has already shown exciting findings, with highly significant reductions in amyloid deposition in cholinesterase inhibitor treated DLB patients.
